Advertisement

Topics

Debiopharm Group Company Profile

06:12 EST 22nd November 2017 | BioPortfolio

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect on HCV replication both in vitro and in vivo. Debio 025 has excellent antiviral activity against a broad range of genotypes (1, 2, 3 and 4); a high barrier to the development of resistance; and the possibility for once daily dosing. It is expected to have a superior safety and efficacy profile to standard of care, and to be efficacious in patients not responding to the standard treatment.


News Articles [276 Associated News Articles listed on BioPortfolio]

Lancement de « patients.debiopharm.com », un site internet sur les essais cliniques de ...

Debiopharm International SA (Debiopharm -  www.debiopharm.com), membre de Debiopharm Group ™, société biopharmaceutique mondiale basée en Suisse, a annoncé aujourd'hui le lancement d'un nouv...

Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com

     (Photo: http://mma.prnewswire.com/media/608971/Debiopharm_International_Website.jpg) Debiopharm's main therapeutic areas are oncology and infectious diseases. The company is currently c...

Arbor Pharmaceuticals, LLC Announces FDA Approval for Triptodur (triptorelin)

Atlanta, GA and Lausanne, Switzerland – June 30, 2017 – Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, and Debiopharm International SA, part of Debiopharm Group™, a S...

FDA Approves Triptodur for Treatment of Patients 2 Years and Older with Central Precocious Puberty

ATLANTA and LAUSANNE, Switzerland, June 30, 2017 /PRNewswire/ — Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, and Debiopharm International SA, part of Debiopharm Gro...

6,8 M€ pour Hybrigenics et 2,23 M€ pour Debiopharm international

Tous les jours un bref écho des principales infos de la veille avec le remindHIER de BiotechFinances Hybrigenics (FR0004153930- ALHYG), nouveaux médicaments contre les maladies prolifératives, a...

Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

The And Debiopharm Announce Winners Of The 2017 JCA-Mauvernay Award

  Life Sciences Jobs   ...

Arbor Pharma And Debiopharm Announce U.S. FDA Approval For Triptodur, Triptorelin 6-Month Formulation, In The Treatment Of Central Precocious Puberty (CPP)

  Life Sciences Jobs   ...

PubMed Articles [1790 Associated PubMed Articles listed on BioPortfolio]

Transcanalicular laser-assisted dacryocystorhinostomy with diode laser.

This article compares the efficacy of transcanalicular laser assisted dacryocystorhinostomy (TL DCR) with conventional external dacryocystorhinostomy (Ex DCR). All patients were randomly divided into ...

Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group.

Protective effects of Tempol in an experimental ovarian ischemia-reperfusion injury model in female Wistar Albino rats.

The aim of this study was to investigate the antioxidant effects of tempol on ovarian ischemia-reperfusion injury in rats. Forty female Wistar albino rats were randomly divided into five groups: Group...

Effects of leptin on femoral fracture in rats.

In this study, our objective was to evaluate effects of leptin on fracture healing in rats. Seventy two male Sprague-Dawley (SD) rats were randomized into 3 groups. Standardized femoral fractures were...

Keeping up appearances: Strategic information exchange by disidentified group members.

Information exchange is a crucial process in groups, but to date, no one has systematically examined how a group member's relationship with a group can undermine this process. The current research exa...

Clinical Trials [3246 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

The Effect of Rhubarb on Sepsis and Post-traumatic Gastrointestinal Function Failure

Random grouping by computer, divided into two groups, a group of rhubarb treatment group, another group for the placebo group.

Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?

The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...

Companies [1581 Associated Companies listed on BioPortfolio]

The Debiopharm Group

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-l...

Debiopharm Galenic Unit

Debiopharm, Debiovision, Debioinnovation, Debio R.P. and Debioclinic form an established group of five complementary and synergistic companies. Together, they provide drug development expertise and kn...

Debiopharm Group

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect o...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

More Information about "Debiopharm Group" on BioPortfolio

We have published hundreds of Debiopharm Group news stories on BioPortfolio along with dozens of Debiopharm Group Clinical Trials and PubMed Articles about Debiopharm Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Debiopharm Group Companies in our database. You can also find out about relevant Debiopharm Group Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record